NO20061619L - Malsoking av tumorvaskulatur ved a benytte radiomerket antistoff L19 mot fibronectin ED-B - Google Patents
Malsoking av tumorvaskulatur ved a benytte radiomerket antistoff L19 mot fibronectin ED-BInfo
- Publication number
- NO20061619L NO20061619L NO20061619A NO20061619A NO20061619L NO 20061619 L NO20061619 L NO 20061619L NO 20061619 A NO20061619 A NO 20061619A NO 20061619 A NO20061619 A NO 20061619A NO 20061619 L NO20061619 L NO 20061619L
- Authority
- NO
- Norway
- Prior art keywords
- domain
- antibody
- cdr1
- cdr2
- seq
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title 2
- 102000016359 Fibronectins Human genes 0.000 title 1
- 108010067306 Fibronectins Proteins 0.000 title 1
- 201000011510 cancer Diseases 0.000 title 1
- 230000036210 malignancy Effects 0.000 title 1
- 210000005166 vasculature Anatomy 0.000 title 1
- 230000009870 specific binding Effects 0.000 abstract 4
- 239000000427 antigen Substances 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 230000027455 binding Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Optics & Photonics (AREA)
- Physics & Mathematics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
Et spesifikt bindingsmedlem som binder humant ED-B, der det spesifikke bindingsmedlemmet er merket med en isotop som er valgt fra gruppen som består av 76Br, 77Br, 123I, 124I, 131I og 211At og som omfatter et antigenbindende sete som omfatter et antistoff-VH-domene og et antistoff-VL-domene, der antistoff-VH-domenet er valgt fra gruppen som består av L19-VH-domenet og et VH-domene som omfatter en VH-CDR1, en VH-CDR2 og en VH-CDR3, der VHCDR3 er L10-VL-CDR3 ifølge Sekv. Id. nr. 3, VH-CDRI er eventuelt L19-VH-CDR1 ifølge Sekv. Id. nr. 1 og VH-CDR2 er eventuelt L19-VH-CDR2 ifølge Sekv. Id. nr. 2, og der antistoff-VL-domenet eventuelt er valgt fra gruppen som består av L19-VL-domenet og et VL-domene som omfatter en VL-CDR1, en VL-CDR2 og en VL-CDR3, der VL-CDR3 er L 19-VL-CDR3 ifølge Sekv. Id. nr. 6, VL-CDR1 er eventuelt L19-VL-CDR1 ifølge Sekv. Id. nr. 4 og VL-CDR2 er eventuelt L19-VL-CDR2 ifølge Sekv. Id. nr. 5, der L19-VH-domenesekvensen og L19-VL-domenesekvensen er tilkjennegjort i Pini et al (1998) J. Biol. Chem. 273: 21769-21776, der det spesifikke bindingsmedlemmet omfatter et mini-immunoglobulin som omfatter nevnte antistoff-VH-domenet og antistoff-VL-domenet fusjonert til eS2-CH4 og dimerisert eller omfatter et helt IgG1 antistoffmolekyl, og også fremgangsmåter og anvendelse som benytter et slikt spesifikt bindingsmedlem.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US50188103P | 2003-09-10 | 2003-09-10 | |
| EP03255633A EP1514561A1 (en) | 2003-09-10 | 2003-09-10 | Targeting of tumor vasculature using radiolabelled antibody L19 against fibronectin ED-B |
| PCT/EP2004/009733 WO2005023318A1 (en) | 2003-09-10 | 2004-09-01 | Targeting of tumor vasculature using radiolabelled antibody l19 against fibronectin ed-b |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NO20061619L true NO20061619L (no) | 2006-04-10 |
Family
ID=34130349
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20061619A NO20061619L (no) | 2003-09-10 | 2006-04-10 | Malsoking av tumorvaskulatur ved a benytte radiomerket antistoff L19 mot fibronectin ED-B |
Country Status (27)
| Country | Link |
|---|---|
| US (2) | US20050074401A1 (no) |
| EP (3) | EP1514561A1 (no) |
| JP (1) | JP2007505065A (no) |
| KR (1) | KR101129161B1 (no) |
| CN (1) | CN100482285C (no) |
| AT (1) | ATE499949T1 (no) |
| AU (2) | AU2004269897B2 (no) |
| BR (1) | BRPI0414272A (no) |
| CA (1) | CA2536256C (no) |
| CR (2) | CR8331A (no) |
| DE (1) | DE602004031635D1 (no) |
| DK (1) | DK1663320T3 (no) |
| EA (1) | EA010653B1 (no) |
| EC (1) | ECSP066499A (no) |
| ES (1) | ES2361743T3 (no) |
| IL (1) | IL173560A0 (no) |
| ME (1) | MEP13108A (no) |
| NO (1) | NO20061619L (no) |
| NZ (1) | NZ545640A (no) |
| PL (1) | PL1663320T3 (no) |
| PT (1) | PT1663320E (no) |
| RS (1) | RS20060176A (no) |
| SG (1) | SG162760A1 (no) |
| SI (1) | SI1663320T1 (no) |
| UA (1) | UA89759C2 (no) |
| WO (1) | WO2005023318A1 (no) |
| ZA (1) | ZA200602014B (no) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU4243201A (en) * | 2000-02-24 | 2001-09-03 | Eidgenoess Tech Hochschule | Antibody specific for the ed-b domain of fibronectin, conjugates comprising saidantibody, and their use for the detection and treatment of angiogenesis |
| JP2005534283A (ja) * | 2002-03-11 | 2005-11-17 | フィロジェン ソチエタ ペル アツィオニ | 抗体分子を用いての腫瘍脈管系の選択的標的化 |
| US7785591B2 (en) | 2004-10-14 | 2010-08-31 | Morphosys Ag | Identification and characterization of function-blocking anti-ED-B-fibronectin antibodies |
| ES2382058T3 (es) * | 2008-01-17 | 2012-06-04 | Philogen S.P.A. | Combinación de una proteína de fusión de un anticuerpo dirigido contra el EDB de la fibronectina-IL-2, y una molécula de unión a los linfocitos B, progenitores de los linfocitos B y/o sus homólogos cancerosos |
| AU2015202204A1 (en) * | 2008-04-30 | 2015-05-14 | Immunogen, Inc. | Cross-linkers and their uses |
| EP2281006B1 (en) * | 2008-04-30 | 2017-08-02 | Immunogen, Inc. | Cross-linkers and their uses |
| WO2011147762A2 (en) * | 2010-05-25 | 2011-12-01 | Bayer Pharma Aktiengesellschaft | Stabilized radiopharmaceutical composition |
| WO2014194784A1 (zh) * | 2013-06-06 | 2014-12-11 | 合肥立方制药股份有限公司 | 人源抗纤连蛋白ed-b结构域的抗体及其用途 |
| GB201621806D0 (en) | 2016-12-21 | 2017-02-01 | Philogen Spa | Immunocytokines with progressive activation mechanism |
| US10517238B2 (en) | 2017-09-18 | 2019-12-31 | Deere & Company | Implement optimization by automated adjustments |
| WO2020249757A1 (en) | 2019-06-14 | 2020-12-17 | Philogen S.P.A | Immunoconjugates comprising a single chain diabody and interleukin-15 or interleukin-15 and a sushi domain of interleukin-15 receptor alpha |
| HRP20241274T1 (hr) | 2020-05-22 | 2024-12-06 | Philogen S.P.A. | Terapija na bazi tnf-a imunokonjugata za liječenje tumora mozga |
| CN111808161A (zh) * | 2020-06-01 | 2020-10-23 | 北京大学 | 一种对生物化合物进行放射性标记的方法 |
| EP4440599B1 (en) | 2022-01-04 | 2026-02-25 | Philogen S.p.A. | Combination of an immunocytokine comprising il-12 and a kinase inhibitor |
| WO2025061801A1 (en) | 2023-09-19 | 2025-03-27 | Philochem Ag | Therapeutic combination of an anti-edb fibronectin domain antibody il2 or il12 fusion protein and a lutetium-177 radioconjugate |
| WO2026003203A1 (en) | 2024-06-27 | 2026-01-02 | Philogen S.P.A. | Combination of an immunocytokine comprising targeted il2 and a jak inhibitor |
| CN119775344B (zh) * | 2024-12-31 | 2025-08-26 | 英科新创（苏州）生物科技有限公司 | 水溶性吖啶磺酰胺衍生物、制备方法、其应用及试剂盒 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| JPS61134325A (ja) | 1984-12-04 | 1986-06-21 | Teijin Ltd | ハイブリツド抗体遺伝子の発現方法 |
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| US20030045681A1 (en) * | 1998-05-11 | 2003-03-06 | Anthony J. Zelano | Specific binding molecules for scintigraphy, conjugates containing them and therapeutic method for treatment of angiogenesis |
| AU4243201A (en) * | 2000-02-24 | 2001-09-03 | Eidgenoess Tech Hochschule | Antibody specific for the ed-b domain of fibronectin, conjugates comprising saidantibody, and their use for the detection and treatment of angiogenesis |
| PT1257297E (pt) | 2000-02-24 | 2006-12-29 | Philogen Spa | Composições e método para tratamento da angiogénese em lesões patológicas |
| AU2001281824A1 (en) * | 2000-06-15 | 2001-12-24 | Patrizia Castellani | Methods for quantitative determination of b-fibronectin in biological fluids and tissues |
| EP2239274A1 (en) * | 2002-01-03 | 2010-10-13 | Bayer Schering Pharma AG | New methods for diagnosis and treatment of tumours |
| JP2005534283A (ja) * | 2002-03-11 | 2005-11-17 | フィロジェン ソチエタ ペル アツィオニ | 抗体分子を用いての腫瘍脈管系の選択的標的化 |
-
2003
- 2003-09-10 EP EP03255633A patent/EP1514561A1/en not_active Withdrawn
-
2004
- 2004-09-01 EA EA200600494A patent/EA010653B1/ru not_active IP Right Cessation
- 2004-09-01 ES ES04764695T patent/ES2361743T3/es not_active Expired - Lifetime
- 2004-09-01 WO PCT/EP2004/009733 patent/WO2005023318A1/en not_active Ceased
- 2004-09-01 EP EP10008347A patent/EP2246070A2/en not_active Withdrawn
- 2004-09-01 PL PL04764695T patent/PL1663320T3/pl unknown
- 2004-09-01 NZ NZ545640A patent/NZ545640A/xx unknown
- 2004-09-01 BR BRPI0414272-1A patent/BRPI0414272A/pt not_active IP Right Cessation
- 2004-09-01 RS YUP-2006/0176A patent/RS20060176A/sr unknown
- 2004-09-01 CA CA2536256A patent/CA2536256C/en not_active Expired - Fee Related
- 2004-09-01 CN CNB2004800260484A patent/CN100482285C/zh not_active Expired - Fee Related
- 2004-09-01 AU AU2004269897A patent/AU2004269897B2/en not_active Ceased
- 2004-09-01 KR KR1020067004816A patent/KR101129161B1/ko not_active Expired - Fee Related
- 2004-09-01 JP JP2006525703A patent/JP2007505065A/ja active Pending
- 2004-09-01 SI SI200431651T patent/SI1663320T1/sl unknown
- 2004-09-01 AT AT04764695T patent/ATE499949T1/de active
- 2004-09-01 UA UAA200603803A patent/UA89759C2/ru unknown
- 2004-09-01 DK DK04764695.5T patent/DK1663320T3/da active
- 2004-09-01 ME MEP-131/08A patent/MEP13108A/xx unknown
- 2004-09-01 PT PT04764695T patent/PT1663320E/pt unknown
- 2004-09-01 EP EP04764695A patent/EP1663320B1/en not_active Expired - Lifetime
- 2004-09-01 DE DE602004031635T patent/DE602004031635D1/de not_active Expired - Lifetime
- 2004-09-01 SG SG201003976-6A patent/SG162760A1/en unknown
- 2004-09-10 US US10/937,882 patent/US20050074401A1/en not_active Abandoned
-
2006
- 2006-02-06 IL IL173560A patent/IL173560A0/en unknown
- 2006-03-09 ZA ZA200602014A patent/ZA200602014B/en unknown
- 2006-04-06 CR CR8331A patent/CR8331A/es unknown
- 2006-04-10 EC EC2006006499A patent/ECSP066499A/es unknown
- 2006-04-10 NO NO20061619A patent/NO20061619L/no not_active Application Discontinuation
-
2009
- 2009-01-08 US US12/350,346 patent/US20090214423A1/en not_active Abandoned
-
2010
- 2010-01-22 AU AU2010200271A patent/AU2010200271A1/en not_active Abandoned
-
2011
- 2011-03-24 CR CR20110168A patent/CR20110168A/es not_active Application Discontinuation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CR20110168A (es) | Reconocimiento dirigido de la vasculatura tumoral usando el anticuerpo l19 contra ed-b de fibronectina marcado radioactivamente (divisional solicitud 8331) | |
| CY1124289T1 (el) | Ανοσοσυζευμα που περιλαμβανει εξανθρωποποιημενα αντισωματα rs7 | |
| HRP20120701T1 (hr) | Humana monoklonska protutijela protiv fukozil-gm1 i postupci za uporabu antifukozil-gm1 | |
| HRP20191462T1 (hr) | Antitijela usmjerena protiv her-3 i njihove uporabe | |
| WO2007062245A3 (en) | Human monoclonal antibody human cd134 (ox40) and methods of making and using same | |
| PE20020871A1 (es) | Moleculas de enlace terapeuticas | |
| HRP20110758T1 (en) | Il-17 antagonistic antibodies | |
| HRP20020693B1 (hr) | HUMANIZIRANA PROTUTIJELA KOJA SADRŽE PEPTID Aß | |
| WO2006089133A3 (en) | Anti-cd19 antibodies and uses in oncology | |
| ATE476994T1 (de) | Antikörper gegen gpnmb und ihre verwendungen | |
| ZA200508389B (en) | Humanized antibodies to interferon alpha receptor-1(IFNAR-1) | |
| WO2006133450A3 (en) | Anti-cd19 antibody therapy for the transplantation | |
| WO2006121852A3 (en) | Anti-cd19 antibody therapy for autoimmune disease | |
| NO20026063D0 (no) | Antistoffer mot human MCP-1 | |
| NO20066052L (no) | Anti-CD3 antistoffer og fremgangsmater for anvendelse derav | |
| WO2005112564A3 (en) | Germline and sequence variants of humanized antibodies and methods of making and using them | |
| WO2006055809A3 (en) | Antibodies against vascular endothelial growth factor receptor-1 | |
| BRPI0414515A (pt) | moléculas de ligação terapêuticas | |
| DK1411962T3 (da) | Terapi for pancreacancer med monoklonalt stof | |
| WO2000074729A3 (en) | Alpha or beta emitters to fragments in radioimmunotherapy | |
| WO2005010153A3 (en) | Antibodies and uses thereof | |
| JP2007508352A5 (no) | ||
| UA84539C2 (ru) | Человеческое моноклональное антитело, которое специфически связывается с cd40, фармацевтическая композиция, которая его содержит, и применение антитела для производства лекарственного средства для лечения cd 40-отрицательной опухоли у человека |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC2A | Withdrawal, rejection or dismissal of laid open patent application |